Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.
Authors
Qihan Fu
Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Qihan Fu , Yiwen Chen , Dabing Huang , Chengxiang Guo , Qi Zhang , Xiang Li , Xiaochen Zhang , Shunliang Gao , Risheng Que , Yan Shen , Jian Wu , Min Zhang , Xueli Bai , Tingbo Liang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03977272
DOI
10.1200/JCO.2022.40.4_suppl.560
Abstract #
560
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).
First Author: Philip Agop Philip
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano